ShangBay Capital

NEWS ALERT – We’re excited to announce the first trans-septal cases using the Luna TMVR system! Many thanks to our physician partners Drs. Adrian Ebner, Irakli Gogorishvili, Azeem Latib, Susheel Kodali, Edwin Ho, Gagan Singh and Vinayak Bapat for their commitment to clinical excellence in these initial cases. Read more in our release ➡ https://prn.to/40gfrtD #TMVR #mitralvalve #structuralheart #innovation #medtech #teamwork #clinicalexcellence #clinicaltrials

Ceribell │ AI-Powered Point-of-Care EEG seeks up to $578M valuation in upsized US IPO https://lnkd.in/gBhUm3dJ

We're pleased to announce that Setpoint has received IDE approval from the FDA to study its proprietary neuroimmune modulation platform in people living with relapsing-remitting multiple sclerosis (RRMS). “We look forward to initiating this pilot study to advance SetPoint's platform in another therapeutic area,” said David Chernoff, M.D., Chief Medical Officer of SetPoint Medical. “The results from our studies in validated preclinical models of MS suggest that the SetPoint System has the potential to address the urgent unmet medical need for novel therapies that reduce demyelination and promote remyelination – providing new hope for people living with MS.” The pilot study will be initiated in 2025 and will enroll up to 60 patients across the United States. Dive into the details here: https://lnkd.in/g6ReKNkc #TheSetPointAdvantage #MultipleSclerosis #RRMS #MS #Autoimmune This communication contains information about a device not yet approved in the United States for commercial use. The Setpoint System is limited by United States law to investigational use only.

Tangible Science is proud to announce our newest product: Tangible Fill Developed in collaboration with VibrantVue®, Tangible Fill is a preservative-free, additive-free saline solution formulated for rinsing GP lenses and rinsing and inserting scleral lenses. Tangible Fill is the newest addition to the Tangible Care System, working seamlessly with Tangible Hydra-PEG, Tangible Boost, and Tangible Clean to provide a complete lens care solution. Key features of Tangible Fill: - Preservative-free and additive-free formulation - Convenient 5mL unit vials (60 per box) - Completes the comprehensive Tangible Care System As eye care professionals and scleral lens wearers know, proper lens care is crucial for comfort, clarity, and eye health. Tangible Fill represents our ongoing commitment to addressing the unique needs of custom contact lens wearers and the practitioners who serve them. Tangible Fill will be available soon. To learn more and sign up for launch notifications, visit: https://lnkd.in/g4wCaCFt #scleral #sclerallens #eyecare #optometry #tangible

Very excited about our latest publication and the encouraging results of AMF treatment combined with antibiotics. #PJI #JointInfections #SolenicMedical

Skyhawk Therapeutics is pleased to present additional topline data from Parts A and B of its Phase 1 clinical trial of SKY-0515 at the European Huntington’s Disease Network and Enroll-HD 2024 meeting in Strasbourg, France. Skyhawk is currently enrolling Huntington’s patients in Part C of its Phase 1 clinical trial and is on track to report topline data from the trial in Q2 2025. Learn More: https://lnkd.in/eJ2Jpf4V #HuntingtonsDisease #EHDN #RareDisease #SkyhawkTx #DrugDevelopment #SmallMoleculeRNA #RNA

🚀 Exciting News! 🚀 We are thrilled to announce Zeto’s new partnership with Firefly Neuroscience! This collaboration brings together Zeto’s advanced EEG platform and Firefly’s Brain Network Analytics (BNA™) technology, enabling clinicians to gain deeper insights and improve patient outcomes more easily. Aswin Gunasekar, Zeto’s Founder and CEO, expressed his excitement about the partnership: “We are excited to partner with Firefly to offer customers more valuable tools, helping expand our user base and improving the value of EEG. By integrating Firefly’s BNA™ offering with Zeto’s EEG platform, we are able to advance our mission of positively impacting patients' lives through transformative, user-friendly, and best-in-class solutions.” 👉 For more details, check out the full press release here: https://lnkd.in/eVXEHYzd #Innovation #BrainHealth #EEG #HealthcareTechnology #Neurology

Venova Medical, Inc. has secured $30M in Series B funding, led by Catalyst Health Ventures and a major medical device company, with participation from multiple investors including ShangBay Capital and Mirae Asset Capital. Congratulations Venova Medical, Inc.! Venova Medical is developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access. https://lnkd.in/gxvkeHEU

ShangBay Capital is proud to announce that Ceribell │ AI-Powered Point-of-Care EEG, one of our first portfolio companies, has officially filed for a $100 million initial public offering. This marks a significant achievement not only for Ceribell but also for our team at ShangBay Capital, reflecting our commitment to backing innovative companies transforming the healthcare landscape. Ceribell has developed a pioneering electroencephalography (EEG) platform that leverages AI-driven algorithms to provide rapid diagnosis and continuous monitoring for patients at risk of seizures. Their technology is setting new standards in neurological care, addressing critical gaps in patient management, and reducing healthcare costs. Since our initial investment, Ceribell has grown to serve over 450 healthcare providers and has been instrumental in improving the lives of more than 100,000 patients. This milestone IPO is a testament to their innovation, dedication, and impact in the field of medical technology. Congratulations to the Ceribell team on reaching this important milestone. ShangBay Capital remains committed to partnering with visionary companies like Ceribell to drive advancements in healthcare. #IPO #HealthcareInnovation #VentureCapital #Neurology #MedicalTechnology https://lnkd.in/gAebHAyG

Skyhawk Therapeutic, a ShangBay’s portfolio company, has postitive news from Phase 1 trial for SKY-0515 that lowers huntingtin and targets somatic expansion……